NCT04473859

Study to Evaluate the Safety of FSR Peptide Versus Placebo Following Punch Biopsy

A Phase 1, Double-blind, Single Center, Controlled Study to Evaluate the Safety and Tolerability of FSR Peptide Versus Placebo Following Punch Biopsy in Adult Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 49 (actual)
• Sponsor: Xequel Bio, Inc. · Academic / Other
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purposes of this study is to test the safety of the study drug (FSR peptide) after a punch biopsy in healthy subjects.

Conditions

• Wound Heal

Interventions

Type	Name	Description
DRUG	FSR Peptide 20μM	Administered immediately after punch-biopsy and 24 hours after punch biopsy.
DRUG	FSR Peptide 50μM	Administered immediately after punch-biopsy and 24 hours after punch biopsy.
DRUG	FSR Peptide 100μM	Administered immediately after punch-biopsy and 24 hours after punch biopsy.
DRUG	FSR Peptide 200μM	Administered immediately after punch-biopsy and 24 hours after punch biopsy.
DRUG	Placebo	Administered immediately after punch-biopsy and 24 hours after punch biopsy.

Timeline

• Start date: 2008-03-06
• Primary completion: 2009-04-28
• Completion: 2009-04-28
• First posted: 2020-07-16
• Last updated: 2020-07-20

Locations

1 site across 1 country: Switzerland

Regulatory

• FDA-regulated drug study